Georgia Medicare Prescription Payment Plan (M3P) Guide 2026

By Brevy Care Team

The Medicare Prescription Payment Plan (M3P) is the fourth pillar of the Inflation Reduction Act's transformative Part D redesign — joining the $2,000 out-of-pocket cap, the Manufacturer Discount Program, and the expanded Low-Income Subsidy. M3P is a voluntary monthly smoothing program that allows Medicare Part D beneficiaries to spread their annual out-of-pocket cost-sharing across equal monthly installments instead of paying lump sums at the pharmacy point of sale.

The mechanic is straightforward but consequential: when a beneficiary opts into M3P, they pay $0 at the pharmacy counter for the rest of the plan year. Their Part D or Medicare Advantage Prescription Drug (MA-PD) plan tracks the cost-sharing the beneficiary would otherwise owe and bills the beneficiary in equal monthly installments through the end of the calendar year. M3P does not reduce the total annual out-of-pocket amount — it only spreads the timing.

For Medicare beneficiaries on high-cost specialty drugs (oncology agents, biologics, MS DMTs), a single January fill can hit the entire $2,000 (2025) / $2,100 (2026) out-of-pocket cap in one transaction. Without M3P, the beneficiary owes the full cap amount at the pharmacy that month — a financial shock for many fixed-income seniors. M3P eliminates this shock by allowing the beneficiary to pay $0 at the pharmacy and instead receive a separate monthly bill from their plan for the smoothed amount (~$175/month if cap is reached in January and the beneficiary opts in immediately).

M3P was established by Section 11202 of the Inflation Reduction Act of 2022 (Public Law 117-169, signed by President Joe Biden on August 16, 2022) and codified at Section 1860D-2(b)(2)(E) of the Social Security Act. It took effect January 1, 2025, simultaneously with the $2,000 Part D out-of-pocket cap. CMS issued the Final Medicare Prescription Payment Plan Guidance Part One in June 2024 and revised guidance in April 2025 for 2026 operational refinements.

Key M3P characteristics:

• Voluntary — beneficiaries opt in; not all enrollees benefit from M3P
• Available all Part D and MA-PD plans — universal offering mandated by Section 1860D-2(b)(2)(E)
• No income means test — any enrollee can opt in
• Does not reduce total — only spreads the timing of beneficiary cost-sharing
• $0 at point of sale + monthly bill — beneficiary pays $0 at pharmacy, plan bills monthly
• Plan-year-specific — opt-in is for the current calendar year; the enrollment resets January 1
• Non-payment consequences — failure to pay monthly bills can result in M3P removal for the rest of the year

For Georgia eldercare specifically, M3P matters because:

• Approximately 1.5+ million Georgia Medicare Part D / MA-PD enrollees can opt in
• Specialty drug users at major Georgia cancer centers (Emory Winship, Piedmont Cancer Institute, Northside Cancer Institute, NGMC oncology, Augusta U Cancer Center) and rheumatology / MS programs benefit most
• LIS beneficiaries typically do not benefit because their already-low copays (~$1.55-$12.15) do not need smoothing
• GeorgiaCares SHIP, Atlanta Legal Aid, and Georgia Area Agencies on Aging provide M3P opt-in counseling

This guide explains M3P in comprehensive detail: the statutory framework, the opt-in process, the monthly billing mechanics, the does-not-reduce-total principle, the beneficiary eligibility, the profiles that benefit most, the LIS/Manufacturer Discount/insulin cap/MFP coordination, the non-payment consequences, and the Georgia-specific considerations.

Key takeaways

• The Medicare Prescription Payment Plan (M3P) is a voluntary monthly smoothing program for Medicare Part D out-of-pocket cost-sharing, established by Section 11202 of the Inflation Reduction Act of 2022 and codified at Section 1860D-2(b)(2)(E) of the Social Security Act
• M3P took effect January 1, 2025, simultaneously with the $2,000 Part D out-of-pocket cap
• M3P allows beneficiaries to pay $0 at the pharmacy and receive monthly bills from their plan instead
• M3P does not reduce total annual cost-sharing — only spreads timing
• M3P is voluntary — any Part D / MA-PD enrollee can opt in, with no income means test
• All Part D and MA-PD plans must offer M3P under Section 1860D-2(b)(2)(E)
• Beneficiaries can opt in any time during the plan year; opt-in resets January 1
• Non-payment consequences: failure to pay monthly bills can result in M3P removal for the rest of the year
• M3P benefits high-cost specialty drug users most — oncology, MS DMTs, autoimmune biologics
• LIS beneficiaries generally do not benefit because their LIS copays are already very low
• M3P coordinates with: $2,000/$2,100 OOP cap, Manufacturer Discount Program (10%/20%), insulin $35 cap, Drug Price Negotiation MFPs (first cycle effective January 1, 2026), and LIS
• For Georgia: ~1.5+ million Part D / MA-PD enrollees; specialty drug users at Emory Winship, Piedmont Cancer Institute, Northside Cancer Institute, NGMC oncology benefit most; GeorgiaCares SHIP provides opt-in counseling

Statutory and regulatory framework

Section 11202 of the Inflation Reduction Act of 2022

Section 11202 of the Inflation Reduction Act of 2022 (Public Law 117-169, signed by President Joe Biden on August 16, 2022) is the primary statutory authority for M3P. Section 11202 is the same section of the IRA that established the Manufacturer Discount Program — Congress paired the two reforms in the same statutory section because they jointly support the IRA Part D redesign.

Key Section 11202 components for M3P:

• Created M3P at new Section 1860D-2(b)(2)(E) of the Social Security Act
• Mandated all Part D and MA-PD plans offer M3P as a benefit option
• Established opt-in mechanism with beneficiary election
• Established does-not-reduce-total principle — M3P spreads timing only
• Coordinated with the $2,000 OOP cap at Section 11201 IRA

Section 1860D-2(b)(2)(E) of the Social Security Act

M3P is codified at Section 1860D-2(b)(2)(E) of the Social Security Act. Key provisions:

• Section 1860D-2(b)(2)(E)(i) — M3P availability and plan offering requirement
• Section 1860D-2(b)(2)(E)(ii) — opt-in process and beneficiary election
• Section 1860D-2(b)(2)(E)(iii) — monthly cap and installment calculation
• Section 1860D-2(b)(2)(E)(iv) — non-payment consequences
• Section 1860D-2(b)(2)(E)(v) — plan reconciliation
• Section 1860D-2(b)(2)(E)(vi) — pharmacy adjudication
• Section 1860D-2(b)(2)(E)(vii) — beneficiary notification

CMS Final M3P Guidance Part One (June 2024)

CMS issued the Final Medicare Prescription Payment Plan Guidance Part One in June 2024. This document covers:

• Beneficiary election process (initial opt-in, retroactive opt-in)
• Plan operational requirements (monthly billing, beneficiary notification, accounting)
• Pharmacy operational requirements (point-of-sale adjudication)
• Initial monthly cap calculation formula
• Reconciliation cycle
• Non-payment grievance and appeal
• Plan-year reset

CMS M3P Guidance Revised (April 2025)

CMS issued revised M3P Guidance in April 2025 for operational refinements for 2026. The revision addressed:

• Refined monthly cap calculation methodology
• Pharmacy claim system updates
• Beneficiary notification timing
• Plan reconciliation efficiency
• Coordination with Drug Price Negotiation MFPs (first cycle effective January 1, 2026)
• Coordination with Manufacturer Discount Program

CMS Plan Bid Instructions annual

CMS issues annual Plan Bid Instructions to Part D and MA-PD plans, which include operational requirements for M3P delivery. Each plan must commit to offering M3P with consistent rules.

CMS M3P Outreach and Education Materials

CMS publishes beneficiary-facing M3P materials including:

• Plain-language M3P fact sheets
• Decision tools (who benefits / who does not benefit)
• Sample opt-in forms
• Sample monthly bills
• Pharmacy notification language

These materials are distributed through 1-800-MEDICARE, Medicare.gov, plan member materials, and partner organizations like GeorgiaCares SHIP.

How M3P works: step-by-step

Step 1: Beneficiary opts in

A Medicare Part D or MA-PD beneficiary opts into M3P by contacting their plan. Three opt-in pathways:

1. Phone: Call the plan's member services line and request M3P enrollment
2. Online: Use the plan's online member portal (if available)
3. Paper: Submit a paper opt-in form to the plan

Opt-in can occur at any time during the plan year. The plan must process the opt-in promptly (typically within 24 hours) and begin M3P operations.

Step 2: Pharmacy adjudicates with $0 cost-sharing

Once M3P is active, at every pharmacy fill:

• Pharmacy submits claim to plan with NDC, days supply, quantity
• Plan adjudicates with beneficiary cost-sharing set to $0
• Pharmacy receives full payment from plan (including the amount the beneficiary would otherwise pay)
• Beneficiary walks out of pharmacy without paying

Step 3: Plan tracks beneficiary cost-sharing internally

The plan tracks the cost-sharing that the beneficiary would have owed at the pharmacy. This is tracked against the beneficiary's TrOOP and the $2,000/$2,100 OOP cap.

The beneficiary's total annual M3P-deferred cost-sharing cannot exceed the OOP cap.

Step 4: Plan calculates monthly billed amount

Each month, the plan calculates:

• Cumulative beneficiary cost-sharing deferred to M3P (year-to-date)
• Remaining months in plan year
• Monthly bill amount = cumulative deferred cost-sharing / remaining months (recalculated monthly to spread evenly)

The calculation is dynamic: if the beneficiary continues to fill prescriptions, the monthly bill may increase mid-year. If the beneficiary stops filling, the monthly bill stabilizes.

Step 5: Plan bills beneficiary monthly

The plan sends a separate monthly bill (distinct from the Part D premium bill) for the M3P installment. The bill includes:

• Monthly installment amount
• Due date (typically end of month or first of following month)
• Total M3P balance year-to-date
• Estimated remaining annual M3P balance

Step 6: Beneficiary pays plan monthly

The beneficiary pays the plan monthly via:

• Check by mail
• Direct debit (ACH)
• Online portal
• Phone payment

The beneficiary does NOT pay the pharmacy (no cost-sharing at point of sale).

Step 7: Plan year reset

On December 31 of each year, the M3P enrollment terminates. Beneficiary must re-opt-in for the next plan year. New plan year starts with $0 M3P balance.

Step 8: Non-payment handling

If the beneficiary fails to pay a monthly M3P bill:

• Plan provides notice and grace period
• Beneficiary can appeal or request reconciliation
• Persistent non-payment may result in M3P removal for the rest of the year
• After removal, the beneficiary resumes standard cost-sharing at the pharmacy
• The plan retains the right to recover unpaid M3P balances

Does-not-reduce-total principle

M3P does not change the total amount the beneficiary owes — it only changes timing.

Example: A beneficiary on Imbruvica with a January fill hits the $2,100 OOP cap on the first fill.

• Without M3P: Beneficiary pays $2,100 at the pharmacy in January, $0 for rest of year.
• With M3P: Beneficiary pays $0 at the pharmacy in January, then plan bills the beneficiary 12 × $175 = $2,100 over 12 months (or 11 × $190.91 if opt-in occurs in February).

Total beneficiary cost = $2,100 either way.

The benefit of M3P is financial smoothing, not cost reduction.

Beneficiary profiles: who benefits, who does not

Beneficiaries who benefit from M3P

1. High-cost specialty drug users with single-fill cap attainment

   • Oncology patients on branded oral agents ($10,000-$20,000+ per fill)
   • MS DMT users ($7,000-$10,000+ per fill)
   • Autoimmune biologic users (Stelara, Enbrel, Humira)
   • Without M3P: $2,100 owed in January
   • With M3P: ~$175/month

2. Beneficiaries with January high-cost fills who cannot afford the lump sum

   • Fixed-income seniors on Social Security
   • Recently retired without significant savings
   • Beneficiaries with cash flow constraints

3. Beneficiaries with multiple high-cost medications mid-year

   • Beneficiaries who hit the cap by May or June
   • Without M3P: cumulative lump-sum impact
   • With M3P: smoothed over remaining months

Beneficiaries who typically do not benefit from M3P

1. LIS beneficiaries

   • LIS copays are very low ($1.55-$12.15)
   • No cash flow stress
   • M3P opt-in adds administrative burden without benefit
   • Recommendation: LIS beneficiaries should generally NOT opt in to M3P

2. Low-cost multi-generic users

   • Beneficiaries with <$50/month in copays
   • No benefit from spreading
   • Recommendation: Do not opt in

3. Beneficiaries near plan-year end

   • Late-year opt-in (e.g., November) provides minimal smoothing benefit
   • Better to wait for January opt-in for new plan year

4. Beneficiaries with cash flow management already

   • Beneficiaries with adequate savings or income
   • Personal preference for paying at pharmacy

Decision support resources

• GeorgiaCares SHIP: 1-866-552-4464 — free M3P decision counseling
• CMS M3P Decision Tool: medicare.gov (interactive tool)
• Plan member services — plan-specific opt-in counseling

Coordination with other IRA programs

Part D out-of-pocket cap ($2,000 / $2,100)

• M3P monthly bills cumulatively cannot exceed the cap
• Once beneficiary reaches the cap, M3P continues to bill the remaining smoothed amount monthly, but no further deferred cost-sharing accrues (catastrophic phase = $0 OOP)
• For specialty drug users, this means M3P pays out the cap over 12 months (typically ~$175/month for $2,100 cap)

Manufacturer Discount Program (10% / 20%)

• Manufacturer discounts in the initial coverage phase count toward TrOOP and reduce plan cost
• Beneficiary cost-sharing (which M3P defers) is calculated on the post-discount price
• Catastrophic phase manufacturer discounts (20%) do not affect beneficiary OOP (already $0)
• M3P is unaffected by Manufacturer Discount Program operations

Insulin $35 cost-sharing cap

• Insulin beneficiaries pay $35/month per insulin product
• M3P can be used for insulin if desired, but $35 is generally manageable
• LIS beneficiaries pay LIS copay (even lower than $35) — M3P typically unnecessary
• M3P + insulin can be useful for beneficiaries with multiple insulins (basal + mealtime + premixed) plus other high-cost drugs

Drug Price Negotiation Program (MFPs)

• First-cycle MFPs effective January 1, 2026 (Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, Fiasp/NovoLog)
• MFP reduces drug price; cost-sharing calculated on MFP
• Combined with Manufacturer Discount + M3P + OOP cap, beneficiary OOP for MFP drugs is dramatically lower
• M3P smooths the post-MFP cost-sharing

Low-Income Subsidy (LIS)

• LIS beneficiaries have copays $1.55-$12.15 per fill
• M3P opt-in adds administrative complexity without financial benefit
• General recommendation: LIS beneficiaries should NOT opt in to M3P
• Limited exceptions: LIS beneficiary with multiple high-cost specialty fills concentrated early in plan year may marginally benefit; usually still better to retain LIS direct-pay model

Pharmacy operational considerations

Real-time adjudication

Pharmacies receive M3P indicators in plan claim responses:

• Beneficiary M3P-enrolled flag
• Beneficiary cost-sharing override to $0
• Plan accepts full payment for the dispensed product

Pharmacy communication

Pharmacies should communicate to M3P beneficiaries:

• "You owe $0 today because you opted into M3P"
• "Your plan will bill you monthly for your cost-sharing"
• "Please contact your plan with any billing questions"

Pharmacy-plan reconciliation

Plans pay pharmacies the full claim amount (cost-sharing + plan payment combined). Pharmacy AR is unaffected by M3P (pharmacy gets paid the same amount).

Plan operational considerations

Plan M3P operations

Each Part D / MA-PD plan must:

1. Process opt-in elections within 24 hours
2. Communicate M3P enrollment to pharmacies
3. Adjudicate claims with $0 beneficiary cost-sharing
4. Track cumulative M3P-deferred cost-sharing per beneficiary
5. Calculate monthly bill amounts
6. Generate monthly bills (separate from Part D premium bills)
7. Process beneficiary payments (mail, ACH, online, phone)
8. Handle non-payment escalation and removal
9. Notify beneficiary of plan-year reset
10. Re-enroll for new plan year if beneficiary re-opts in

Plan reconciliation with CMS

CMS reconciles M3P operations with plans through standard Part D plan reconciliation processes. M3P does not change total federal Part D outlays — only beneficiary timing.

Georgia-specific impact

Population

• ~1.5+ million Georgia Medicare beneficiaries enrolled in Part D / MA-PD
• All can opt into M3P
• ~300,000+ LIS beneficiaries (M3P generally not beneficial)
• ~50,000-100,000 estimated potential M3P beneficiaries (high-cost specialty drug users + cash flow constraints)

Major Georgia specialty drug centers

• Emory Winship Cancer Institute (Atlanta) — oncology, pharmacy navigation
• Piedmont Cancer Institute (Atlanta, Marietta, Columbus, Fayette, Newnan, Athens) — oncology, pharmacy support
• Northside Cancer Institute (Atlanta, Forsyth, Cherokee, Gwinnett) — oncology
• NGMC oncology (Gainesville) — north Georgia oncology
• Augusta University Cancer Center — east Georgia oncology
• Atrium Health Navicent Cancer Center (Macon) — central Georgia oncology
• Memorial Health Cancer Center (Savannah) — coastal Georgia oncology
• Phoebe Putney Cancer Center (Albany) — southwest Georgia oncology
• WellStar MS Center (Marietta) — MS DMT management
• Emory Neurology (Atlanta) — MS, neurology
• Emory Rheumatology (Atlanta) — autoimmune biologics
• Atrium Navicent Rheumatology (Macon) — autoimmune

Pharmacy navigation programs

Major Georgia academic medical centers (Emory, NGMC, Piedmont, Augusta U) have pharmacy navigators trained in IRA Part D mechanics including M3P opt-in counseling.

GeorgiaCares SHIP M3P counseling

GeorgiaCares SHIP (1-866-552-4464) provides:

• M3P opt-in/decline decision support
• Annual review during AEP (October 15-December 7)
• Year-round telephone counseling
• Plan-specific M3P comparison

14 best practices for Georgia seniors and families

1. Use the CMS M3P Decision Tool at medicare.gov before opting in — confirms whether M3P benefits your specific situation.

2. Opt in at the beginning of the plan year (January) if you expect to hit the OOP cap quickly — maximizes monthly smoothing benefit.

3. Consider M3P if you take any drug exceeding $1,000/month in cost-sharing — single-fill cap attainment makes smoothing valuable.

4. Avoid M3P if you receive LIS — LIS copays are already very low; M3P adds complexity without benefit.

5. Coordinate M3P with your pharmacy navigator — Emory Winship, Piedmont Cancer Institute, NGMC oncology have navigators trained in M3P enrollment.

6. Set up automatic payment for monthly M3P bills — prevents missed payments and M3P removal.

7. Budget monthly for the M3P installment — typically ~$175/month at full cap; integrate into monthly budget.

8. Review your monthly bill carefully — the bill amount can change month-to-month as cumulative cost-sharing increases.

9. Contact GeorgiaCares SHIP (1-866-552-4464) for free M3P opt-in counseling.

10. Re-evaluate M3P annually during AEP (October 15-December 7) — plan-year reset means you must re-opt-in if you still want M3P.

11. Combine M3P with Drug Price Negotiation MFPs — for first-cycle drugs effective January 1, 2026, MFP reduces price; M3P smooths the remaining cost-sharing.

12. Verify pharmacy is adjudicating M3P correctly — pharmacy should charge $0 if M3P is active. If charged, request plan correction.

13. Avoid late-year opt-in — opting in in November or December provides minimal smoothing benefit; wait for January.

14. Maintain contact with plan during M3P — keep plan contact information current; plans send monthly bills and notifications.

14 common issues and how to resolve them

1. M3P opt-in not active after election — Contact plan; verify processing. SHIP can escalate.

2. Pharmacy charged copay despite M3P enrollment — Plan-pharmacy data sync issue. Request retroactive correction. Pharmacy submits adjustment claim.

3. Monthly M3P bill higher than expected — Cumulative cost-sharing increased mid-month; verify against EOB. Plan recalculates monthly bill dynamically.

4. Missed M3P payment — Plan provides grace period; contact plan immediately to avoid removal.

5. M3P removal for non-payment — Removal is for remainder of plan year. Beneficiary resumes standard cost-sharing. Re-opt-in possible next plan year.

6. Confusion between M3P bill and Part D premium bill — These are separate. M3P bill is for cost-sharing smoothing; Part D premium is for plan enrollment. Plan should send separately.

7. M3P does not reduce my total — should I opt in? — M3P provides cash flow smoothing, not cost reduction. Decide based on monthly budget capacity vs lump-sum capacity.

8. LIS beneficiary mistakenly opted into M3P — Generally minimal harm. Can opt out by contacting plan.

9. Switching Part D plans mid-year while in M3P — M3P enrollment ends with plan change. New plan requires fresh opt-in. Cumulative cost-sharing transfers to TrOOP under new plan.

10. M3P during Medicare-Medicaid dual eligibility changes — Becoming a full dual-eligible triggers LIS, which may make M3P unnecessary. Contact plan and SHIP.

11. M3P during AEP plan switching — Opt out before December 31; re-opt-in with new plan in January for new plan year.

12. Pharmacy receiving partial payment due to M3P confusion — Plans pay pharmacies the full amount; pharmacy AR should be unaffected. Verify with pharmacy claims processing.

13. M3P after reaching OOP cap — Beneficiary continues monthly M3P bills (smoothing the cap amount); no further accrual since catastrophic = $0 OOP.

14. M3P interaction with manufacturer Patient Assistance Programs — Manufacturer PAPs may provide additional support; M3P does not preclude PAP. Coordinate with PAP and plan.

Worked examples

Example 1: Fulton 70 — Atlanta CLL Imbruvica M3P

Profile: 70-year-old Atlanta retiree, CLL, Emory Winship Cancer Institute, Imbruvica (ibrutinib) daily, $9,319/30-day MFP 2026 (38% reduction from 2023 list).

Without M3P:

• January 2026 first fill: $615 deductible + 25% coinsurance + 10% manufacturer discount = full $2,100 OOP cap hit at pharmacy
• $0 at pharmacy rest of 2026
• January cash flow: $2,100 in single transaction

With M3P (opt-in January 1):

• January 2026 first fill: $0 at pharmacy
• Plan bills $175/month for 12 months ($175 × 12 = $2,100)
• Total beneficiary cost: $2,100 (same)
• Monthly cash flow: $175/month (manageable)

Emory Winship pharmacy navigator facilitates M3P opt-in.

Example 2: DeKalb 75 — Dual-LIS no M3P benefit

Profile: 75-year-old DeKalb full dual-eligible, 7 medications.

LIS copays: ~$150-250 annual OOP, spread naturally across 12 months.

M3P opt-in analysis:

• LIS copays already very low (~$15-25/month)
• M3P would add administrative burden
• Recommendation: Do NOT opt into M3P

Example 3: Cobb 68 — MS DMT M3P

Profile: 68-year-old Cobb relapsing-remitting MS, WellStar MS Center, oral DMT at $7,800/30-day.

Without M3P:

• January 2026 first fill: $2,100 cap hit at pharmacy
• $0 rest of year

With M3P (opt-in January):

• January 2026 first fill: $0 at pharmacy
• Plan bills $175/month for 12 months

WellStar pharmacy navigator facilitates opt-in.

Example 4: Worth 72 — Rural mid-year M3P opt-in

Profile: 72-year-old Worth County rural resident, 8 medications including Nucala biologic.

Pre-May: Beneficiary not on M3P, paid lump sums at pharmacy. Mid-May: Cumulative cost-sharing approaching $1,500. Beneficiary opts into M3P in May. May-December: $0 at pharmacy; plan bills remaining ~$600 over 7 remaining months = ~$86/month Phoebe Putney pharmacy facilitates opt-in.

Note: Mid-year opt-in provides reduced benefit; ideally opt in at January for full 12-month smoothing.

Example 5: Bibb 80 — Stelara MFP + M3P

Profile: 80-year-old Bibb County (Macon), severe psoriatic arthritis, Atrium Navicent Rheumatology, Stelara every 8 weeks.

2026 scenario with M3P:

• Stelara MFP $4,695/dose (66% reduction from 2023 list)
• First January 2026 dose: deductible $615 + 25% coinsurance on $4,080 + 10% manufacturer discount = $2,100 cap hit
• With M3P: $0 at pharmacy, $175/month for 12 months
• Subsequent doses: $0 OOP (catastrophic phase)
• M3P continues monthly billing through December

Atrium Navicent Rheumatology pharmacy coordinates opt-in.

Example 6: Hall 67 — Imbruvica MFP + M3P at NGMC

Profile: 67-year-old Hall County (Gainesville), CLL, NGMC oncology, Imbruvica daily.

Similar to Example 1 (Fulton):

• Imbruvica MFP $9,319/30-day 2026
• January first fill: $2,100 cap hit; $0 rest of year
• With M3P: $175/month over 12 months

NGMC oncology pharmacy navigator facilitates opt-in.

Frequently asked questions

1. What is the Medicare Prescription Payment Plan (M3P)?

M3P is a voluntary monthly smoothing program for Medicare Part D out-of-pocket cost-sharing. Beneficiaries pay $0 at the pharmacy and instead receive monthly bills from their plan. M3P spreads but does not reduce total annual cost-sharing.

2. When did M3P take effect?

January 1, 2025, simultaneously with the $2,000 Part D out-of-pocket cap.

3. Who is eligible for M3P?

Any Medicare Part D or MA-PD plan enrollee can opt in. No income means test.

4. How do I opt in?

Contact your Part D / MA-PD plan: phone, online portal, or paper form. Plan must process within 24 hours.

5. When can I opt in?

Any time during the plan year. Opt-in is plan-year-specific; resets January 1.

6. Does M3P reduce my total cost?

No. M3P only spreads timing. Total beneficiary cost is the same with or without M3P.

7. How much will I pay monthly?

The plan calculates monthly bill = cumulative deferred cost-sharing / remaining months. For a beneficiary who hits the $2,100 cap in January with January opt-in: ~$175/month for 12 months. Mid-year opt-in: higher monthly amount over fewer months.

8. What happens if I miss a payment?

Plan provides notice and grace period. Persistent non-payment results in M3P removal for the rest of the year. Beneficiary resumes standard cost-sharing.

9. Can I re-enroll if I'm removed?

Yes, for the next plan year. Cannot re-enroll mid-year after removal.

10. Does M3P apply to my Part D premium?

No. M3P is for cost-sharing only. Premiums are billed separately.

11. Should LIS beneficiaries opt into M3P?

Generally no. LIS copays are very low; M3P adds administrative burden without benefit. Limited exceptions for specific high-cost early-year scenarios.

12. Should I opt into M3P if I take only generic drugs?

Probably not. Low-cost generics provide minimal benefit from smoothing.

13. How does M3P coordinate with the Manufacturer Discount Program?

Manufacturer discounts apply automatically at the pharmacy. M3P defers the beneficiary's portion (post-discount). Combined effects: lower per-fill cost-sharing + monthly smoothing.

14. How does M3P coordinate with the insulin $35 cap?

Insulin beneficiaries pay $35/month per insulin product. M3P can defer this, but $35 is typically manageable without smoothing.

15. How does M3P coordinate with the Drug Price Negotiation Program MFPs?

For first-cycle MFP drugs (effective January 1, 2026), MFP reduces price; cost-sharing calculated on MFP; M3P smooths the cost-sharing.

16. What happens if I switch Part D plans mid-year?

M3P enrollment ends with plan change. New plan requires fresh opt-in. TrOOP transfers.

17. What happens when the plan year ends?

December 31, M3P enrollment terminates. Plan year resets January 1; must re-opt-in.

18. Can my plan refuse to offer M3P?

No. All Part D and MA-PD plans must offer M3P under Section 1860D-2(b)(2)(E) SSA.

19. Are there any income limits for M3P?

No. M3P is available to all enrollees regardless of income.

20. Can I opt out of M3P mid-year?

Yes. Contact your plan to opt out. Remaining M3P balance becomes due on a schedule the plan determines.

21. Does M3P affect my Part D plan choice during AEP?

Indirectly. All plans must offer M3P, so M3P availability is not a differentiating factor.

22. Can my family member or caregiver help me with M3P?

Yes. With your authorization, family members or caregivers can manage M3P opt-in, monthly payments, and plan communications.

23. Where can I get M3P decision counseling in Georgia?

GeorgiaCares SHIP: 1-866-552-4464 (free counseling). Many Georgia cancer centers have pharmacy navigators trained in M3P.

24. Is M3P different from the Coverage Gap Discount Program (CGDP) it replaced?

M3P is not a replacement for CGDP. The Manufacturer Discount Program (Section 11202 IRA, Section 1860D-14C SSA) replaced CGDP. M3P is a separate new program for beneficiary cost-sharing smoothing.

25. Where can I get more information?

Medicare 1-800-MEDICARE; CMS M3P at cms.gov; GeorgiaCares SHIP 1-866-552-4464.

Get help

• Medicare: 1-800-MEDICARE (1-800-633-4227), Medicare.gov
• CMS M3P: cms.gov/inflation-reduction-act-and-medicare/medicare-prescription-payment-plan
• GeorgiaCares SHIP: 1-866-552-4464
• Medicare Rights Center: 1-800-333-4114
• Patient Advocate Foundation: 1-800-532-5274
• NeedyMeds: 1-800-503-6897
• Georgia DCH Member Services: 1-866-211-0950
• Atlanta Legal Aid: 404-377-0701
• GA Legal Services: 1-800-498-9469
• Eldercare Locator: 1-800-677-1116
• 211 Georgia: 211.org
• SSA: 1-800-772-1213
• Humana: 1-800-457-4708
• UnitedHealthcare Medicare: 1-800-721-0627
• Aetna Medicare: 1-800-282-5366
• American Cancer Society: 1-800-227-2345
• MS Association of America: 1-800-532-7667
• Cancer Support Community: 1-888-793-9355

This article is part of Brevy's Georgia Medicaid and Medicare resource library. Last verified May 14, 2026. The Medicare Prescription Payment Plan operational details are subject to CMS guidance updates; verify current policy at cms.gov.